Evidence map›Paper›PMID 34438985›Full record

ReviewAntibiotics (Basel, Switzerland)2021

Antibiotics Prescribing in Intensive Care Settings during the COVID-19 Era: A Systematic Review.

Lubna I Abu-Rub, Hana A Abdelrahman, Al-Reem A Johar, Hashim A Alhussain, Hamad Abdel Hadi, Nahla O Eltai

Abstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Journal of clinical medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lubna I Abu-RubBiomedical Research Center, Qatar University, Doha 2713, Qatar.
Hana A AbdelrahmanBiomedical Research Center, Qatar University, Doha 2713, Qatar.
Al-Reem A JoharBarzan Holdings, Doha 7178, Qatar.
Hashim A AlhussainBiomedical Research Center, Qatar University, Doha 2713, Qatar.ORCID 0000-0002-0502-965X
Hamad Abdel HadiCommunicable Diseases Centre, Infectious Disease Division, Hamad Medical Corporation, Doha 3050, Qatar.
Nahla O EltaiBiomedical Research Center, Qatar University, Doha 2713, Qatar.

Funding

Barzan holdings Barzan holdings _BRC1
6 · The paper itself

Abstract

The prevalence of patients admitted to intensive care units (ICUs) with SARS-CoV-2 infection who were prescribed antibiotics is undetermined and might contribute to the increased global antibiotic resistance. This systematic review evaluates the prevalence of antibiotic prescribing in patients admitted to ICUs with SARS-CoV-2 infection using PRISMA guidelines. We searched and scrutinized results from PubMed and ScienceDirect databases for published literature restricted to the English language up to 11 May 2021. In addition, we included observational studies of humans with laboratory-confirmed SARS-CoV-2 infection, clinical characteristics, and antibiotics prescribed for ICU patients with SARS-CoV-2 infections. A total of 361 studies were identified, but only 38 were included in the final analysis. Antibiotic prescribing data were available from 2715 patients, of which prevalence of 71% was reported in old age patients with a mean age of 62.7 years. From the reported studies, third generation cephalosporin had the highest frequency amongst reviewed studies (36.8%) followed by azithromycin (34.2%). The estimated bacterial infection in 12 reported studies was 30.8% produced by 15 different bacterial species, and

Indexed as

antibioticantibiotic prescriptionbacterial co-infectionsCOVID-19ICUSARS-CoV-2

Identifiers

PMID34438985
PMCPMC8389042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.